Targeted disruption of the JAK2/STAT3 pathway in combination with systemic administration of paclitaxel inhibits the priming of ovarian cancer stem-like cells leading to a reduced tumor burden

Targeted disruption of the JAK2/STAT3 pathway in combination with systemic administration of paclitaxel inhibits the priming of ovarian cancer stem-like cells leading to a reduced tumor burden

Chemotherapy resistance associated with recurrent disease is the major cause of poor survival of ovarian cancer patients. We have recently demonstrated activation of the JAK2/STAT3 pathway and the enhancement of a cancer stem cell (CSC)-like phenotype in ovarian cancer cells treated in vitro with ch...

Full description

Bibliographic Details
Main Authors: Khalid eAbubaker, Rodney B Luwor, Ruth eEscalona, Orla eMcNally, Michael A Quinn, Erik W Thompson, Jock K Findlay, Nuzhat eAhmed
Format: Article
Language:English
Published: Frontiers Media S.A. 2014-04-01
Series:Frontiers in Oncology
Subjects:
Recurrence
metastasis
cancer stem cells
chemoresistance
ovarian carcinoma
JAK2/STAT3 pathway
Online Access:http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00075/full

Similar Items

Similar Items